Patent SG-11201907607V-A (SG)
Title: Use of biomarkers in identifying cancer patients that will be responsive to treatment with a prmt5 inhibitor
Inventor: BREHMER DIRK
IPC: G01N33/574
Filed: 2018-02-26
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 30 August 2018 (30.08.2018) WIP0 I PCT omit VIII °nolo OH 100 mil Holum oimIE (10) International Publication Number WO 2018/154104 Al (51) International Patent Classification: C12Q 1/48 (2006.01) G01N 33/574 (2006.01) C12Q 1/68 (2018.01) (21) International Application Number: PCT/EP2018/054644 (22) International Filing Date: 26 February 2018 (26.02.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/464006 27 February 2017 (27.02.2017) US (71) Applicant: JANSSEN PHARMACEUTICA NV [BE/BE]; Turnhoutseweg 30, 2340 Beerse (BE). (72) Inventors: BREHMER, Dirk; Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse (BE). BEKE, Lijs; Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse (BE). GAFFNEY, Dana, Suzanne; Janssen Research & Devel- opment, LLC, 920 US Route 202, PO Box 300, Raritan, NJ 08869 (US). MOY, Christopher, H; Janssen Research & Development, LLC, 920 US Route 202, PO Box 300, Rar- itan, NJ 08869 (US). (74) Agent: VANDERSTEEN, Pieter; J&J Patent Law Depart- ment, Turnhoutseweg 30, 2340 Beerse (BE). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: — with international search report (Art. 21(3)) O 00 O C (54) Title: USE OF BIOMARKERS IN IDENTIFYING CANCER PATIENTS THAT WILL BE RESPONSIVE TO TREATMENT WITH A PRMT5 INHIBITOR (57) : The present invention concerns a method of identifying a patient that is likely to be responsive to treatment with a protein arginine N-methyltransferase 5 (PRMT5) inhibitor comprising: evaluating a biological sample from the patient for the presence of a spliceosome alteration, wherein the presence of any said alteration indicates a higher likelihood for said patient to be responsive to treatment with said PRMT5 inhibitor than in the absence of any said mutation or alteration.